Clinical trials at the Clínica Universidad de Navarra
The Clinic is the private centre that promotes the largest number of clinical trials in Spain. We aim to generate knowledge in order to change the course of diseases.
Learn about our available clinical trials
If you are a patient
Whether you have an illness, have a family member in that circumstance or simply require some information
If you are a healthcare professional
Access to all studies and clinical trials aimed at healthcare professionals
The Clinic's clinical trials offer new possibilities and therapeutic advances to our patients
What is a clinical trial?
A clinical trial with medicines is an investigation carried out on human beings that aims to describe or check the effects of these medicines in order to define their effectiveness and safety.
To highlight the relevance of clinical trials, it is important to emphasize that almost all treatments available today are the direct result of clinical research.
These studies are the opportunity for a new therapeutic line for patients who have exhausted all standard treatments.
Some drugs or medical treatments may not be available, except for use within a clinical trial.
What is the process like?
Not everyone can participate in a clinical trial. Therefore, the research team will evaluate a series of inclusion and exclusion criteria that will determine if their participation in the study is possible.
Your participation is completely voluntary. You may refuse to participate either at the beginning or at any time during the trial, without any harm to you or affecting your medical care.
Learn more about clinical trials
Studies in healthy volunteers or in a selected population of patients suffering from a certain disease, according to the properties of the drug, aimed at determining the first safety and tolerability data of the drug. They can also evaluate the handling of the drug by the organism and estimate the pharmacological activity, generally looking for an adequate dose to move on to Phase II.
The new drug is administered to a limited number of sick patients for a short period of time. The aim is to obtain preliminary information on its safety and the benefits with respect to the treatment or prevention of the disease. Unlike Phase I, the patients in the Phase II have the disease they are trying to fight.
This is the final stage in the process of testing a new drug in humans. Once the Phase III studies are completed and the sponsor can demonstrate that the drug is safe and effective under certain conditions, it is ready for the Administration to approve its release to the market. In this phase, the number of sick patients to whom the new drug is administered is much higher.
It takes place once the drug is already on the market. It usually measures the long-term effects of the new drug or studies new indications.
When everyone involved in the trial knows the treatment being administered.
Researchers know the treatment being used, but patients do not know which of them is being given the drug and who is receiving a placebo.
The information of who is receiving the treatment is withheld from both the researchers and the participants. Only the researchers could get to know the medication given to the patient if necessary to protect the patient's safety.